Switzerland's Novocure Q3 revenue rises 16%, beats estimates
Overview
Global oncology company's Q3 revenue rose 16% yr/yr, beating analyst expectations
Company raised full-year 2026 revenue and adjusted EBITDA guidance
Optune Pax approved in Japan for locally advanced pancreatic cancer
Outlook
Novocure raises 2026 net revenue guidance to $736 mln-$743 mln from $710 mln-$725 mln
Company lifts 2026 adjusted EBITDA forecast to $24 mln-$34 mln from $0 mln-$15 mln
Novocure expects quarterly gross margin in the mid-to-high 70s percent for 2026
Result Drivers
ACTIVE PATIENT GROWTH - Co said 19% global growth in active patients drove Q3 revenue increase
PRODUCT LAUNCHES IN NEW MARKETS - Co attributed record number of active patients to expanding portfolio and new market launches, per CEO Frank Leonard
ONE-TIME CLAIMS APPROVAL BENEFITS - Co recognized $4.4 mln in net revenue from one-time increases in claims approval rates in US and Germany
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $193.40 mln | $182.23 mln (7 Analysts) |
Q3 Net Loss | $10.44 mln | ||
Q3 Gross Profit | $148.87 mln | ||
Q3 Operating Income | -$6.17 mln | ||
Q3 Pretax Loss | $7.88 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for NovoCure Limited is $26.00, about 83.5% above its October 28 closing price of $14.17
Reuters Recommended Reads
Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption
Oct 28 - Glaukos Q3 revenue jumps 58% on iDose TR, Epioxa launches, Corneal Health growth
Oct 28 - Straumann sees North America stabilising, China demand improving after Q3 beat
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)